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Introduction:Hemolytic-uremic syndrome (HUS) is a common cause for intrarenal acute
kidney injury in childhood. More than 90% of HUS cases are associated with an infection
by Shigatoxin-producing Escherichia coli (STEC) whereas the reminder comprises a
heterogeneous group (here classified as Non-STEC-HUS). Renal impairment can persist
in patients with HUS. This study presents data from four decades investigating the
short- and long-term outcome of HUS in childhood.
Materials and Methods: In a retrospective single-center-study clinical and laboratory
data of the acute phase and of 1- to 10-year follow-up visits of children with HUS were
analyzed.
Results: 92 HUS-patients were identified from 1996 to 2014 (STEC-HUS-group:
n= 76; Non-STEC-HUS-group: n= 16) and 220 HUS-patients between 1976 and 1995.
STEC-HUS was increasingly caused by Non-O157 strains and mortality rate declined
over the past decades (1.3 vs. 9.5%). Renal sequelae persisted more often in the group
1976–1995 (39.3%) than in the group 1996–2014 (28.3%), but more than 50% of all
patients were lost to follow-up.
Conclusion: Although renal outcome has improved over the investigated last decades,
patients with HUS still face a high risk of permanent renal damage. These findings
underline the importance of a consequent long-term follow-up in HUS-patients.
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INTRODUCTION
Hemolytic-uremic syndrome (HUS) is defined by a triad of microangiopathic hemolytic anemia,
thrombocytopenia and acute kidney injury and belongs to the heterogeneous group of thrombotic
microangiopathy (TMA) (1–3).
HUS is a rare disease with the highest incidence in young childhood (6/100,000 children <5
years) in Western Europe and USA (2, 4), where it is a common cause for intrarenal acute kidney
injury (AKI) (5). Most cases occur sporadically, but epidemic outbreaks are seen from time to time
(e.g., Germany, 2011) (6).
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Traditionally, HUS was classified by clinical presentation in
prodromal phase as Diarrhea-positive (D+) or typical HUS and
Diarrhea-negative (D−) or atypical HUS. The former primarily
resulted from Shigatoxin-producing Escherichia coli (STEC)
infections and accounts for more than 90% of HUS cases in
childhood and adolescence (7). All other cases were summarized
as atypical, Diarrhea-negative HUS, even though some of these
patients also presented with diarrhea.
A novel etiology-based classification has evolved (8), which
was recently adapted to our national guideline1 as
1. STEC-HUS (formerly typical or Diarrhea-associated HUS)
2. Pneumococcus associated HUS
3. Complement-mediated HUS
4. Other types of HUS (e.g., Cobalamin-C- or DGKE-mutations,
drugs, medication, systemic lupus erythematosus or
pregnancy)
STEC-HUS is usually caused by an infection with STEC or,
less frequent, Shigella dysenteriae Type 1. Typically, affected
children are between 2 and 5 years of age. Patients with STEC-
HUS present with diarrhea, often bloody, in the prodromal
phase. Renal impairment occurs usually 7–14 days after infection.
Extrarenal complications occur more frequently in central
nervous system, but are also seen in pancreas, gastrointestinal
tract and cardiorespiratory system (4, 9, 10).
In most cases, the diagnosis of STEC-HUS can be made
by (typical) medical history, clinical presentation and
(basic) laboratory diagnostics. In patients with STEC-HUS
or Pneumococcus associated HUS a pathogen detection (blood
and/or stool sample) should be obtained. In patients with
complement-mediated HUS detailed complement diagnostics,
including genetic analysis, in specialized laboratories are
necessary.
Therapy during the acute phase is basically supportive. 50–
70% of patients with HUS need renal replacement therapy and up
to 80% require transfusions (red blood cells, platelets) (5, 11, 12).
Eculizumab, a monoclonal C5 antibody, significantly improved
renal outcome and survival of patients with complement-
mediated HUS (13, 14).
Mortality in the acute phase is low (<5%) (15), but renal
impairment persists in up to 30% of patients with STEC-HUS
(12, 16).
In this single-center-study we investigated data of our
HUS-patients of four decades with the aim to improve the
understanding of short- and long-term outcome of HUS
in childhood and identifying prognostic markers at first
presentation.
PATIENTS AND METHODS
In a retrospective single-center-study we investigated clinical and
laboratory data out of the acute phase and the 1- to 10-year
follow-up visits in children diagnosed with HUS between the
years 1976 and 2014.
1AWMF: Detail. Available online at: http://www.awmf.org/leitlinien/detail/ll/166-
002.html (Accessed April 28, 2018).
Patients were divided in two groups, according to time of
diagnosis and etiology.
Patients with onset between 1996 and 2014 were assigned
to either STEC-HUS- or Non-STEC-HUS-group (group 2).
Detection of EHEC/STEC or Shigatoxin (stx) in stool or blood
sample or typical clinical presentation with (bloody) diarrhea, age
of onset 2–5 years and neither relapse nor familiarity attributed
patients to STEC-HUS-group. All other patients were included as
Non-STEC-HUS-group.
All patients with disease onset between 1976 and 1995
were summarized as group 1 or a historical cohort. In this
group, differentiation between STEC- and Non-STEC-HUS was
not feasible due to insufficient/non-existent data on EHEC/stx
detection and complement diagnostics.
We investigated demographic (gender, age, body height,
and weight), clinical (symptoms, arterial blood pressure and
extrarenal complications) and laboratory data (hemoglobin,
platelet count, leucocyte count, serum creatinine (Jaffe or
enzymatic method), estimated glomerular filtration rate (eGFR),
urinary output, complement factor C3, proteinuria) and
medication (antihypertensive drugs, renal replacement therapy,
transfusions) on admission and during the acute phase. Follow-
up parameters (arterial blood pressure, need for antihypertensive
medication, eGFR and proteinuria) were investigated at onset
and thereafter once a year until transition to adult medical
care. eGFR was calculated by updated Schwartz’ formula and, if
available in early cases, results of the isotope clearance method
were also collected (17, 18).
Blood pressure was measured with an appropriately sized cuff
either by oscillometric devices or by auscultation. Because of
insufficient data (height and weight) in follow-up visits age- and
gender-adjusted percentiles derived from 24 h ambulatory blood
pressure monitoring were applied (19, 20).
Surrogates for possible kidney injury were defined as
the presence of at least one of the following parameters:
proteinuria ≥300 mg/l or ≥1+ on dipstick, mean arterial
pressure (MAP) >90th Percentile (adjusted for age and
sex) (20), need for antihypertensive medication, and eGFR
<90 ml/min/1.73 m². Renal sequelae were defined as
need for antihypertensive medication and/or eGFR <90
ml/min/1.73 m².
Statistics
SPSS Version 22 (IBM, 2013) and Microsoft Excel (2013)
were used for data collection and statistical analysis. Normality
of variables was tested by Kolmogorov–Smirnov Test. As for
bivariate statistics, the dependence between the data was tested
using Fisher’s exact test (small sample size, frequency <5) or chi2
test for count data. Mann–Whitney U-test was used to compare
continuous variables. P < 0.05 were considered statistically
significant.
Ethical Approval
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and national research committee and with the
1964 Helsinki declaration and its later amendments.
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FIGURE 1 | Study collective.
RESULTS
Study Collective
In total, 326 children with the diagnosis of HUS have been
identified between 1976 and 2014. 14 patients (4.3%) were
excluded due to insufficient data (Figure 1). There was an almost
similar frequency of females (52.6%) and males (47.4%).
Most of the patients were treated in the time period
between 1976 and 1995 (220 patients, 70.5%). In the
second period, 76 patients with STEC-HUS and 16 patients
with Non-STEC-HUS-group were treated in our hospital
(Figure 1).
Epidemiology and Etiology
Group 1 (1976–1995, n = 220)
We identified 220 children with the diagnosis of HUS between
1976 and 1995 (115 females, 105 males). Their median age was
1.88 years [0.3; 17.0].
Group 2 STEC-HUS-GRoup (1996–2014, n = 76)
76 children (44 girls, 32 boys) with STEC-HUS were identified
between 1996 and 2014. Their median age was 3.0 years
[0.3; 15.7]. Most cases occurred between the months May
and September. Clinical HUS diagnosis was confirmed by
microbiological analysis in 88% of the patients. Most frequently
detected pathogen was EHEC O157 (41/76 STEC-HUS-patients,
54%) (Figure 2). Shigatoxin was detected in 73% (40/55),
especially stx 2 in 63% (35/50).
Group 2 Non-STEC-HUS-Group (1996–2014, n = 16)
We identified 16 patients (five females, 11 males, median
age 2.4 years, [0.4; 20.0]) with Non-STEC-HUS from 1996
to 2014. Patients with Non-STEC-HUS were observed during
all seasons. Different etiologies for Non-STEC-HUS were
observed, most common was Pneumococcus associated HUS
and complement-mediated HUS (Table 1). Five patients were
classified into the Non-STEC HUS group despite diarrhea.
These patients had Pneumococcal HUS (n = 1), Aeromonas
TABLE 1 | Cohort of patients with Non-STEC-HUS.
Post-infectious 6
- S. pneumoniae 5
- Aeromonas spp. 1
Complement-mediated 5
- Factor-H-antibodies + CFHR-deficiency 3
- Familial 2
MMACHC†-mutation 1
Bone marrow transplantation 1
Etiology unknown 3
†
MMACHC, methylmalonic aciduria and homocystinuria type C protein. Bold values
represent the sum of each category.
associated HUS (n = 1) and complement-mediated HUS
(n = 3). Complement-mediated, familial HUS was diagnosed
in two cases: one boy had two episodes of HUS without
signs of infections. His older brother had also recurrent HUS
episodes. The other boy had also HUS without signs of
infection. His mother and grandmother had had recurrent HUS
episodes.
The three patients, which we classified as unknown etiology
(Table 1), had no reported diarrhea, low C3 serum and negative
results for EHEC diagnostic.
Laboratory Data, Clinical Presentation and
Therapy (Acute Phase)
Most patients with STEC-HUS presented with a prodromal phase
of 5 days with diarrhea (90.5%), often bloody, vomiting and
fever. These symptoms were seen less frequently in patients
with Non-STEC-HUS (diarrhea 33.3%). Median duration of the
prodromal phase in patients with Non-STEC-HUS was 3 days,
clinical presentation varied.
Acute renal failure was similar in both groups [STEC-
HUS 44/62 (71.0%), Non-STEC-HUS 10/13 (76.9%)], but the
need of antihypertensive medication was higher in Non-
STEC-HUS-group (35.1% vs. 56.3%). Extrarenal manifestations
were encountered more frequently in Non-STEC-HUS-group
(Table 2). Decrease in complement factor C3 was seen in 19% of
STEC-HUS- and 50% of Non-STEC-HUS-group.
59 of 76 children with STEC-HUS (77.6%) and 13 of
16 patients with Non-STEC-HUS (81.3%) needed renal
replacement therapy. Plasmapheresis was performed in nine
STEC-HUS-patients (11.8%) and four Non-STEC-HUS-patients
(25.0%). One patient with Non-STEC-HUS received Eculizumab
(Table 2).
75 of 76 (98.7%) patients with STEC-HUS and 15 of 16
(92.8%) Non-STEC-HUS-patients survived the acute phase.
Compared to the historical group (group 1), mortality rate in the
acute phase was significantly lower (1.3 vs. 9.5%, p= 0.018) in the
STEC-HUS-group.
Long-Term Follow-Up
It was recommended to all patients with HUS to adhere to regular
follow-up visits. However, a high proportion of patients was lost
to follow-up (Figure 3).
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FIGURE 2 | Results of microbiological analysis in patients with STEC-HUS. In 12% clinical diagnosis of STEC-HUS was suspected without detection of E. coli.
At 1 year follow-up, 53 of 75 (70.6%) patients with STEC-HUS
were seen in the outpatient ward. 21 of these patients (39.6%)
were identified to have surrogates for possible kidney injury.
Renal sequelae showed 15 patients (28%). 8 of 15 (53.3%) patients
with Non-STEC-HUS were seen at follow-up and all of these
had renal sequelae. In the historical group, 145 of 199 patients
(72.8%) were seen and 72 (49.7%) had surrogates for possible
kidney injury. 57 (39.3%) presented with renal sequelae.
At 5 year follow-up, 9/18 STEC-HUS-patients (50.0%) had
surrogates for possible kidney injury; 8 (44.4%) had renal
sequelae. 6/6 Non-STEC-HUS-patients seen in the outpatient
ward had renal sequelae. In the historical cohort 34/59 of patients
(57.6%) who were seen after 5 years showed surrogates for renal
damage and 24 (40.7%) had renal sequelae.
At 10 year follow-up, 7/9 STEC-HUS-patients (77.8%) and 3/3
Non-STEC-HUS-patients who came to follow-up showed renal
sequelae. 17/21 patients from the historical cohort (81.0%) had
surrogates for possible kidney injury, 15 of these (71.4%) had
renal sequelae.
Rate of renal transplantations was significantly higher in
patients with Non-STEC-HUS (31.3%) in comparison to STEC-
HUS-group (6.7%, p= 0.004) (Table 2).
Risk-Factors for Potential Renal Damage
We found the strongest correlation between antihypertensive
therapy during the acute phase as well as anuria >7 days
and surrogates for possible kidney injury in 1- to 5-year
follow-up (STEC-HUS-group and historical cohort, Table 3).
No significant correlations (p ≥ 0.05) were found for platelet
count <50/nl or GFR <20 ml/min/1.73 m² on admission as
well as age or sex (STEC-HUS-group and historical cohort).
Extrarenal involvement (central nervous system/pancreas)
was not a significant risk-factor for surrogates for possible
kidney injury (p ≥ 0.05) in 1- to 5-year follow-up. In the
STEC-HUS-group, 18 patients had central nervous system
involvement and four patients pancreatic affection. Out of
these patients 10 had surrogates for possible kidney injury,
seven showed no signs of renal damage and five patients
were lost to follow up. Decrease of complement factor C3
and proof of Shigatoxin 2 (stx 2) were not associated with
surrogates for possible kidney injury in the STEC-HUS-group
(1996–2014).
DISCUSSION
In this study we report on 312 children, which is one of the largest
HUS cohorts published. We analyzed epidemiological, clinical
and laboratory data as well as follow-up data up to 10 years.
One of the challenges, reporting about HUS in the past decades,
is how to consider the changes in pathophysiology and disease
classification. Primarily, HUS classification was orientated by
clinical manifestations (D+/D− HUS, typical/atypical HUS). In
contrast, in the recent years, a more detailed classification was
established (8). Therefore, we decided to report about a historical
cohort (group 1) between 1976 and 1995, where differentiation
between D+/D− or typical/atypical HUS would be speculative,
and a cohort between 1996 and 2014 (group 2). With regard to
the current knowledge in pathophysiology we sorted the patients
into a STEC-HUS- or Non-STEC-HUS-group.
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TABLE 2 | Laboratory data, clinical presentation, therapy and mortality rate during acute phase (STEC- and Non-STEC-HUS-group, 1996–2014).
STEC-HUS-group
(1996–2014, n = 76)
Non-STEC-HUS-group
(1996–2014, n = 16)
p
Laboratory data
median (n) [range] median (n) [range]
- Hemoglobin (admission) 8.8 g/dl (72) [3.9–15.5] 8.7 g/dl (16) [4.3–14.6]
- White blood cells (admission) 15/nl (73) [4.2–43.0] 11/nl (16) [4.8–20.2]
- Platelets (min) 44/nl (73) [9.0–414.0] 21/nl (15) [8.0–142.0]
- Se-creatinine (max) 4.6 mg/dl (73) [0.34–11.6] 3.7 mg/dl (14) [1.0–9.1]
- Complement factor C3 ↓ 11/58 = 19% 5/10 = 50% 0.033
Clinical presentation
(“yes”/n) % (“yes”/n) %
Diarrhea 67/74 90.5 5/15 33.3 0.000
- Bloody 28/74 37.8
Fever 15/74 20.3 5/15 33.3 0.419
Renal manifestation
- Olig-/anuria 44/62 71.0 10/13 76.9 0.664
- Anuria > 7 days 9 7
- Antihypertensive medication 26/74 35.1 9/16 56.3 0.116
Extrarenal manifestation
- Central nervous system 18/75 24.3 6/16 37.5 0.266
- Pancreas 4/75 5.3 1/15 6.7 0.837
Therapy
(“yes”/n) % (“yes”/n) %
Dialysis 59/76 77.6 13/16 81.3 0.750
- HD† 6 4
- PD‡ 45 6
- PD and HD 8 3
Plasmapheresis 9/76 11.8 4/16 25.0 0.170
Eculizumab 0 1
Antihypertensive medication 26/74 35.1 9/16 56.3 0.116
Transfusions
- Red blood cells 63/75 84.0 9/16 56.3 0.013
- Platelets 8/74 10.8 5/16 31.3 0.035
- Fresh frozen plasma 5/74 6.8 5/16 31.3 0.005
Mortality rate (acute phase) 1/76 1.3 1/16 6.3 0.219




PD, peritoneal dialysis; ↓Decreased complement C3 level.
In STEC-HUS-group females and males were affected equally
and age of onset was similar to Non-STEC-HUS-group. STEC-
HUS most commonly occurred during the summer season
whereas Non-STEC-HUS cases were observed all over the year.
This data confirms other cohort studies (21–23). EHEC O157
still was the most common strain in STEC-HUS-group, but as
observed in other national and international cohorts, Non-O157
strains become more prevalent (21, 24, 25).
In the acute phase of illness, as shown in Table 2, neither
laboratory nor clinical data allowed an absolute discrimination
between STEC-HUS and Non-STEC-HUS. In our cohort, one
third of Non-STEC-HUS-patients presented with diarrhea and
fever, on the other hand almost 20% of STEC-HUS-patients
showed signs of complement activation (decrease of serum C3).
In the Non-STEC-HUS group might be cases of STEC-HUS.
Missing detection of STEC does not exclude STEC-HUS (26).
However, in our Non-STEC-HUS group are only three patients
with unknown etiology. These patients had low serum C3 levels,
no reported diarrhea and negative results for EHEC diagnostic.
Differentiation between STEC- and Non-STEC-HUS is
further complicated by the fact that stx can trigger complement-
dependent microvascular thrombosis (27). These observations
might justify the use of eculizumab in severe cases of STEC-HUS
with neurological disorders (28).
Compared to other recently published cohort studies (21–23),
the frequency of renal replacement therapy was higher in our
patients with almost 80%. Additionally frequency of patients with
HUS was declining in our hospital over the past decades. One
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FIGURE 3 | Long-term follow-up and potential renal damage (1976–2014).









Groups hist.† STEC hist. STEC hist. STEC hist. STEC
AHT§ 0.003 0.003 n.s.¶ <0.0001 0.022 0.023 0.029 0.029
Anuria >7 days <0.0001 0.038 0.01 0.028 0.004 n.s. 0.025 n.s.
Leukocytes >20/nl 0.01 n.s. 0.02 n.s. n.s. 0.007 0.006 n.s.
Dialysis n.s. 0.002 n.s. 0.031 n.s. n.s. n.s. n.s.
Corresponding p-values are shown.
†
hist., historical cohort (1976–1995, group 1); STEC, STEC-HUS-group (1996–2014); §AHT, antihypertensive therapy; ¶n.s., not significant (p ≥
0.05).
reason for these aspects might be that more patients without need
of renal replacement therapy are treated in other hospitals.
The need of antihypertensive medication was higher in Non-
STEC-HUS-group than in STEC-HUS-group.
Mortality rate was low for STEC-HUS (1.3%) and Non-STEC-
HUS-group (6.3%) and declined compared to historical group
(9.5%) as better treatment options, especially for Non-STEC-
HUS, are available. Compared to other cohorts mortality rate was
comparable low (15, 21, 22).
Renal impairment persists in 25–30% of patients with
EHEC/Diarrhea associated HUS (12, 16). Elevated white blood
cell count at the beginning of the illness, antihypertensive therapy
during acute phase and extrarenal involvement (particularly
central nervous system and pancreas) are described as risk-
factors for renal sequelae. Furthermore, the duration of olig-
/anuria, as well as need for renal replacement therapy may be
associated to a worse renal long-term outcome (12, 16, 29, 30).
In our study, we confirmed that anuria for more than 7 days
and the need of antihypertensive therapy in the acute phase
of illness strongly correlate with surrogates for possible kidney
injury after 1–5 years (STEC-HUS-group and historical cohort).
In contrast, platelet count <50/nl, GFR <20 ml/min/1.73 m² or
extrarenal involvement were no risk-factors for surrogates for
possible kidney injury in our study collective.
We saw a steady lost to follow-up over the years, meanwhile
proportion of patients with renal damage who came to follow-up
was increasing through the years. There might be some selection
bias over time. However, in our study, almost one third of
children with possible kidney injury are lost to follow up. Nearly
one sixth of children who were classified with no signs of renal
damage in the first year follow-up visit showed surrogates for
possible kidney injury 1 year later on.
Low follow-up rates were also seen in other cohort studies
(21, 22).
It seems to be very difficult to reach adequate follow-up rate,
even in a single center. Achieving improvement here seems to be
very important, as a high proportion of our patients has persistent
renal sequelae.
There are several limitations in our study. First, we performed
a retrospective single-center-study and therefore missed the
advantages of prospective multicenter trials. Further, data
collection was incomplete in some cases. As our study covered
almost four decades, diagnostic tests and classifications changed
over this period, so we had to work with several compromises in
describing our patient cohort. Our study was monocentric and
as children without complete renal failure (and without need
of renal replacement therapy) may have been treated in other
hospitals, we have some bias here regarding incidence rate and
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severity of clinical course. As in other cohort studies, we have
low follow-up rates and therefore can only speculate about real
incidence of renal sequelae after HUS. Finally, we did not register
data about the severity of renal sequelae in detail.
In conclusion, our report points at the fact that all patients,
irrespective of their HUS origin, strictly should be followed on
a long-term basis because of the high impact of renal sequelae
for their further life. In order to reach an improvement here,
national or international guidelines should be implemented with
detailed information and instruction for consequent follow-up in
all patients. Further, national or international registries could be
implemented in order to measure and improve renal outcome
after HUS.
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